UK Markets closed
  • FTSE 100

    7,083.37
    +102.39 (+1.47%)
     
  • FTSE 250

    23,784.54
    +173.15 (+0.73%)
     
  • AIM

    1,268.13
    +8.00 (+0.63%)
     
  • GBP/EUR

    1.1642
    -0.0005 (-0.04%)
     
  • GBP/USD

    1.3619
    -0.0045 (-0.3282%)
     
  • BTC-GBP

    31,285.58
    -1,563.38 (-4.76%)
     
  • CMC Crypto 200

    1,089.55
    +49.07 (+4.72%)
     
  • S&P 500

    4,395.64
    +41.45 (+0.95%)
     
  • DOW

    34,258.32
    +338.48 (+1.00%)
     
  • CRUDE OIL

    70.51
    -0.05 (-0.07%)
     
  • GOLD FUTURES

    1,768.40
    -9.80 (-0.55%)
     
  • NIKKEI 225

    29,639.40
    -200.31 (-0.67%)
     
  • HANG SENG

    24,221.54
    +122.40 (+0.51%)
     
  • DAX

    15,506.74
    +158.21 (+1.03%)
     
  • CAC 40

    6,637.00
    +84.27 (+1.29%)
     

2021 Hybrid/Virtual/Decentralized Clinical Trials Market Outlook

·4-min read

Dublin, Aug. 05, 2021 (GLOBE NEWSWIRE) -- The "Hybrid/Virtual/Decentralized Clinical Trials Market Outlook" report has been added to ResearchAndMarkets.com's offering.

Change is hard and it can certainly be intimidating, especially in an area like drug development when there is much at stake and many complexities to manage.

Enter COVID-19.

The industry had no choice but to adapt to maintain any sort of momentum on clinical development activities. The hybrid model quickly became essential for allowing patients to continue with their trials amidst a global pandemic and the myriad health and logistical concerns that accompanied it.

The publisher surveyed 109 respondents at sponsors and CROs regarding their experiences with hybrid trials and providers of these services. Though not all reported a smooth, pain-free experience, nearly two-thirds of respondents came away with a positive overall impression of hybrid trials.

Furthermore, respondents do not seem to consider the hybrid trial model as a temporary solution to be discarded after the pandemic has subsided. 83% of respondents expect that the hybrid trial model will be used more frequently than the traditional trial model three years from now. These data are saying loud and clear that hybrid trials are here to stay.

What You Will Learn:

Pharmaceutical Organizations:

  • Learn from survey-takers verbatim responses on "lessons learned" from conducting hybrid trials and which aspects of hybrid trials have worked well for them

  • Plan ahead for managing your hybrid trials by understanding which components are considered easier to manage in a hybrid trial vs. in a traditional trial model

  • Make more informed provider selections by knowing how industry peers select hybrid trial providers and how providers have performed for recent users

  • Discover in which areas related to hybrid trials companies are investing significant resources

Service Providers:

  • Understand the selection drivers most important to sponsors when choosing hybrid trial providers

  • Learn how users of hybrid trials view your company (and your competitors) along brand metrics of leadership, familiarity with hybrid trial offerings, proposal requests, reported use, and how providers performed compared to their expectations

  • Discover which technologies respondents believe need the most improvement to meet hybrid trial needs and read, in respondents' own words, their unmet technology-related needs

Major Topics:

  • Hybrid Trial Use and Experience

  • Provider Selection

  • Provider Perceptions

  • Future Predictions

  • Study Data

Key Topics Covered:

1. Hybrid Trial Use and Experience

  • Primary Section Takeaways

  • Terminology Used

  • Utilization of Virtual Components

  • Managing Trial Components: Hybrid vs. Traditional Models

  • Overall Hybrid Trial Experience

  • Lessons Learned

  • Aspects That Have Gone Well

  • Aspects That Have Been Frustrating

  • Potential Benefits to Patients

  • Potential Benefits to Sites

  • Potential Benefits to Sponsors/CROs

  • Primary Hybrid Trial Challenge

  • Technologies Needing Improvement

2. Provider Selection

  • Primary Section Takeaways

  • Selection Drivers for Hybrid Trial Providers

  • Trust in Providers' Hybrid Trial Offerings

  • Sponsor Influence over Selection of Apps, Device, or Platforms when Monitoring is Outsourced

  • Departmental Influence over Selection of Apps, Device, or Platforms when Monitoring is In-house

3. Provider Perceptions

  • Primary Section Takeaways

  • Unaided Hybrid Trial Provider Leadership

  • Hybrid Trial Provider Metrics

  • Hybrid Trial Provider Performance

4. Future Predictions

  • Primary Section Takeaways

  • Hybrid vs. Traditional Trial Use in Three Years

  • Areas of Investment

  • Hybrid vs. Traditional Trial Costs

5. Study Data

  • Terminology Used

  • Hybrid Trial Use

  • Utilization of Virtual Components

  • Managing Trial Components: Hybrid vs. Traditional Models

  • Overall Hybrid Trial Experience

  • Lessons Learned

  • Aspects That Have Gone Well

  • Aspects That Have Been Frustrating

  • Potential Benefits to Patients

  • Potential Benefits to Sites

  • Potential Benefits to Sponsors/CROs

  • Challenges of Hybrid Trials

  • Primary Hybrid Trial Challenge

  • Whether Clinical Technologies Meet Hybrid Trial Needs

  • Technologies Needing Improvement

  • Unmet Needs by Technology

    • eCOA

    • ePRO

    • Telehealth/video visit software

    • Wearable sensors/connected health devices

    • Patient-facing web portals

  • In-house vs. Outsourced Hybrid Trials

  • Sponsor Influence over Selection of Apps, Device, or Platforms when Monitoring is Outsourced

  • Departmental Influence over Selection of Apps, Device, or Platforms when Monitoring is In-house

  • Selection Drivers for Hybrid Trial Providers

  • Trust in Providers' Hybrid Trial Offerings

  • Unaided Hybrid Trial Provider Leadership

  • Aided Hybrid Trial Provider Leadership

  • Familiarity with Providers' Hybrid Trial Offerings

  • Hybrid Trial Proposal Requests

  • Use of Hybrid Trial Providers

  • Hybrid Trial Provider Performance

  • Provider Performance Rating Explanations

    • Covance

    • ERT

    • ICON

    • IQVIA

    • Medable

    • Medidata

    • Medpace

    • Oracle

    • Parexel

    • PPD

    • PRA Health Sciences

    • Premier Research

    • Science 37

    • Signant Health (including Virtrial)

    • Syneos

    • Thread

    • Veeva

    • Worldwide Clinical Trials

  • Hybrid vs. Traditional Trial Costs

  • Areas of Investment

  • Hybrid vs. Traditional Trial Use in Three Years

6. Demographics

  • Company Type

  • Company Size

  • Office Location

  • Job Level

  • Decision-making Responsibility

  • Outsourcing Involvement by Phase

  • Involvement in Hybrid Trials

  • Number of Hybrid Trials

For more information about this report visit https://www.researchandmarkets.com/r/w5kr4u


CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting